Biotech
Lifshitz Law Firm, P.C. Announces Investigation of ARPO, CNBKA, CHAQ, DSSI, INSW, FORE, FTIV, ONB, FMBI, and GRA
Lifshitz Law Firm, P.C. Announces Investigation of ARPO, CNBKA, CHAQ, DSSI, INSW, FORE, FTIV, ONB, FMBI, and GRA PR Newswire NEW YORK , June 11, 2021 /PRNewswire/ — Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO) Lifshitz Law more...
Biotech
Ampio Pharmaceuticals to Participate in the Alliance Global Partners’ Virtual Summer Healthcare Symposium
Ampio Pharmaceuticals to Participate in the Alliance Global Partners’ Virtual Summer Healthcare Symposium PR Newswire ENGLEWOOD, Colo. , June 11, 2021 /PRNewswire/ — Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on more...
Biotech
Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density
SEATTLE, June 11, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer more...
Biotech
Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes – Updated data show marrow blast reductions in 10 out more...
Biotech
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity 93% overall response rate and 67% complete response rate in patients treated with modified cell manufacturing process more...
Biotech
Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
Treatment with CYAD-211 generally well-tolerated at first two dose levels, with no evidence of Graft-versus-Host Disease observed Two partial responses observed among five evaluable patients Cell engraftment of CYAD-211 observed in all patients from dose more...
Biotech
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates PFPT, MDP, CHMA, EQT; Shareholders are Encouraged to Contact the Firm
NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) — Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Proofpoint, Inc. (NASDAQ: PFPT) concerning potential violations of the federal securities more...
Biotech
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SWN, ESXB, TGRF, ARPO; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / June 10, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Southwestern Energy Company (NYSE:SWN) concerning potential violations of the more...
Biotech
aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody
Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2. aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are implicated in immune-mediated diseases. SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) more...
Biotech
Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors
Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors – Mani Mohindru, Ph.D., Chief Executive Officer of Novasenta, an early-stage biopharmaceutical company, has deep expertise in all phases of more...